# A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients

> **NCT00261521** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 596 (actual)

## Conditions studied

- Kidney Failure, Chronic
- Anemia

## Interventions

- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00261521
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** —
- **Final completion:** 2003-05
- **Target enrollment:** 596 (ACTUAL)
- **Last updated:** 2010-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00261521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00261521, "A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00261521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*